<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Park J</submitter><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Heart, Lung, and Blood Institute</funding><funding>NIMHD NIH HHS</funding><funding>National Institutes of Health</funding><funding>National Institute on Minority Health and Health Disparities</funding><funding>NIGMS NIH HHS</funding><pagination>1151780</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10106598</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Monocytes and macrophages play a pivotal role in inflammation during acute SARS-CoV-2 infection. However, their contribution to the development of post-acute sequelae of SARS-CoV-2 infection (PASC) are not fully elucidated.&lt;h4>Methods&lt;/h4>A cross-sectional study was conducted comparing plasma cytokine and monocyte levels among three groups: participants with pulmonary PASC (PPASC) with a reduced predicted diffusing capacity for carbon monoxide [DLCOc, &lt;80%; (PG)]; fully recovered from SARS-CoV-2 with no residual symptoms (recovered group, RG); and negative for SARS-CoV-2 (negative group, NG). The expressions of cytokines were measured in plasma of study cohort by Luminex assay. The percentages and numbers of monocyte subsets (classical, intermediate, and non-classical mo</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals.</pubmed_title><pmcid>PMC10106598</pmcid><funding_grant_id>P30 GM114737</funding_grant_id><funding_grant_id>K12 HL143960</funding_grant_id><funding_grant_id>P30 AI027757</funding_grant_id><funding_grant_id>U54 MD007601</funding_grant_id><funding_grant_id>T37 MD008636</funding_grant_id><funding_grant_id>T37MD008638, U54MD007601, P30GM114737</funding_grant_id><funding_grant_id>P30AI027757</funding_grant_id><funding_grant_id>K12HL143960</funding_grant_id><funding_grant_id>U54 GM138062</funding_grant_id><pubmed_authors>Devendra G</pubmed_authors><pubmed_authors>Ching LL</pubmed_authors><pubmed_authors>Dean LS</pubmed_authors><pubmed_authors>Park J</pubmed_authors><pubmed_authors>Shah P</pubmed_authors><pubmed_authors>Igno F</pubmed_authors><pubmed_authors>Gangcuangco LM</pubmed_authors><pubmed_authors>Awamura T</pubmed_authors><pubmed_authors>Nerurkar VR</pubmed_authors><pubmed_authors>Jiyarom B</pubmed_authors><pubmed_authors>Chow DC</pubmed_authors><pubmed_authors>Shikuma CM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals.</name><description>&lt;h4>Background&lt;/h4>Monocytes and macrophages play a pivotal role in inflammation during acute SARS-CoV-2 infection. However, their contribution to the development of post-acute sequelae of SARS-CoV-2 infection (PASC) are not fully elucidated.&lt;h4>Methods&lt;/h4>A cross-sectional study was conducted comparing plasma cytokine and monocyte levels among three groups: participants with pulmonary PASC (PPASC) with a reduced predicted diffusing capacity for carbon monoxide [DLCOc, &lt;80%; (PG)]; fully recovered from SARS-CoV-2 with no residual symptoms (recovered group, RG); and negative for SARS-CoV-2 (negative group, NG). The expressions of cytokines were measured in plasma of study cohort by Luminex assay. The percentages and numbers of monocyte subsets (classical, intermediate, and non-classical mo</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-06-21T03:19:45.668Z</modification><creation>2025-04-07T01:11:46.091Z</creation></dates><accession>S-EPMC10106598</accession><cross_references><pubmed>37077911</pubmed><doi>10.3389/fimmu.2023.1151780</doi></cross_references></HashMap>